Correspondence
To the Editor:
We read with interest the recent article entitled "Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration" by Do et al. 1 With the exception of an earlier (uncited) abstract by two of the authors (D.V. Do and Q.D. Nguyen), 2 there have been virtually no experimental data publicly available on the pharmacokinetics of aflibercept in human eyes. After carefully reviewing Table 1 , we believe that the reported median concentrations contain multiple errors, and the half-life value of 11 days derived from them is incorrect. The erroneous median values apparently resulted from inclusion of the time points along with the concentrations.
Using the five individual subjects' data reported in Table 1 , we recalculated the median values for each time point and obtained the following: 0, 104, 65.9, 51.5, 42.0, 20.3, and 9.35 mg/L, shown in the semilogarithmic plot ( Figure 1 ). Fitting these data to an exponential function (noncompartmental analysis, Certara Phoenix software v. 6.4) yielded a decay rate of 0.072 day 21 and a corresponding half-life of 9.6 days. Similarly, an noncompartmental analysis half-life of 9.5 days was obtained using the mean concentration data. Noncompartmental analysis of individual data showed high intersubject variability, with half-life estimates ranging from 3.7 days to 13.2 days (median and mean: 8.8 days). In aggregate, our analyses suggest that the correct ocular half-life of aflibercept in the human eye is circa 9 days, consistent with what Do and Nguyen 2 reported in their earlier published abstract.
In view of the importance of the ocular half-life as a factor in determining the duration of biological and clinical effects after intravitreal injection, 3 it is important to obtain and report accurate pharmacokinetic data on such ophthalmic products.
Although the experimental study by Do et al 1 seems to have been well designed and performed, the analysis and conclusions reported in the article are flawed. We hope the authors will also perform a reanalysis of their data and correct this. We thank the authors Norman Mazer, MD, PhD, and Antonello Caruso, PhD of "Letter to the Editor" for their comments in response to our article on the pharmacokinetics of intravitreal aflibercept in humans with neovascular age-related macular degeneration. 1 We appreciate this discussion of our work. Shortly after submittal of this manuscript, we also observed that the median values per time point presented in Table 1 and in the text were incorrect in this preproofed version of the paper. These values will be corrected in the final proofs. The median half-life was determined by 1) This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. 
